Unknown

Dataset Information

0

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.


ABSTRACT: Clinically validated biomarkers for anti-angiogenesis agents are not available. We have previously reported associations between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E2100. The associations between tumor VEGFA amplification and outcome are evaluated here.E2100 was a phase III trial comparing paclitaxel with or without bevacizumab for patients with metastatic breast cancer. FISH to assess gene amplification status for VEGFA was conducted on paraffin-embedded tumors from 363 patients in E2100. Evaluation for association between amplification status and outcomes was conducted.Estrogen receptor (ER)+ or progesterone receptor (PR)+ tumors were less likely to have VEGFA amplification than ER/PR- tumors (P = 0.020). VEGFA amplification was associated with worse OS (20.2 vs. 25.3 months; P = 0.013) in univariate analysis with a trend for worse OS in multivariate analysis (P = 0.08). There was a significant interaction between VEGFA amplification, hormone receptor status, and study arm. Patients with VEGFA amplification and triple-negative breast cancers (TNBC) or HER2 amplification had inferior OS (P = 0.047); amplification did not affect OS for those who were ER+ or PR+ and HER2-. Those who received bevacizumab with VEGFA amplification had inferior progression-free survival (PFS; P = 0.010) and OS (P = 0.042); no association was seen in the control arm. Test for interaction between study arm and VEGFA amplification with OS was not significant.VEGFA amplification in univariate analysis was associated with poor outcomes; this was particularly prominent in HER2+ or TNBCs. Additional studies are necessary to confirm the trend for poor OS seen on multivariate analysis for patients treated with bevacizumab.

SUBMITTER: Schneider BP 

PROVIDER: S-EPMC3594423 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.

Schneider Bryan P BP   Gray Robert J RJ   Radovich Milan M   Shen Fei F   Vance Gail G   Li Lang L   Jiang Guanglong G   Miller Kathy D KD   Gralow Julie R JR   Dickler Maura N MN   Cobleigh Melody A MA   Perez Edith A EA   Shenkier Tamara N TN   Vang Nielsen Kirsten K   Müller Sven S   Thor Ann A   Sledge George W GW   Sparano Joseph A JA   Davidson Nancy E NE   Badve Sunil S SS  

Clinical cancer research : an official journal of the American Association for Cancer Research 20130122 5


<h4>Purpose</h4>Clinically validated biomarkers for anti-angiogenesis agents are not available. We have previously reported associations between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E2100. The associations between tumor VEGFA amplification and outcome are evaluated here.<h4>Experimental design</h4>E2100 was a phase III trial comparing paclitaxel with or without bevacizumab for patients with metastatic breast cancer. FISH to assess gene amplification  ...[more]

Similar Datasets

| S-EPMC4453857 | biostudies-literature
| S-EPMC5029696 | biostudies-literature
| S-EPMC6317286 | biostudies-literature
| S-EPMC5902232 | biostudies-literature
| S-EPMC9806434 | biostudies-literature
| S-EPMC3394977 | biostudies-literature
| S-EPMC8405478 | biostudies-literature
| S-EPMC7073274 | biostudies-literature
| S-EPMC5580299 | biostudies-literature
| S-EPMC2799052 | biostudies-literature